Halozyme Therapeutics, Inc. (HALO)

Market Cap	7.11B
Revenue (ttm)	1.02B
Net Income (ttm)	444.09M
Shares Out	123.15M
EPS (ttm)	3.43
PE Ratio	16.84
Forward PE	11.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,193,622
Open	58.00
Previous Close	57.44
Day's Range	57.32 - 58.74
52-Week Range	37.73 - 65.53
Beta	1.25
Analysts	Buy
Price Target	62.78 (+8.71%)
Earnings Date	Feb 18, 2025

About HALO

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 350
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Analyst Forecast

According to 9 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $62.78, which is an increase of 8.71% from the latest price.

Price Target

$62.78

(8.71% upside)

Analyst Consensus: Buy